Morris, H; Wallach, J. From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 614-632. 942 kB. https://doi.org/10.1002/dta.1620 #Lefetamine
Wink, CSD; Meyer, GMJ; Wissenbach, DK; Jacobsen-Bauer, A; Meyer, MR; Maurer, HH. Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): Metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-HR-MS/MS. Drug Test. Anal., 1 Oct 2014, 6 (10), 1038-1048. 674 kB. https://doi.org/10.1002/dta.1621 #Lefetamine
Westphal, F; Junge, T; Jacobsen-Bauer, A; Rõsner, P. Lefetamin-Derivate: alte Bekannte neu auf dem Drogenmarkt. Toxichem Krimtech, 1 Jan 2010, 77 (1), 46–58. 115 kB. #1 MS
Wallach, J; Brandt, SD. 1,2-Diarylethylamine- and ketamine-based new psychoactive substances. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 305-352. 593 kB. https://doi.org/10.1007/164_2018_148 #Lefetamine
EMCDDA. Report on the risk assessment of MT-45, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Oct 2015. 814 kB. #Lefetamine MS,IR,UV